A phase II clinical trial in pre-surgical patients with BC showed that genistein decreased EGFR phosphorylation and downstream phosphorylated MAPK in cancer cells, although this was not translated in notable differences as far as tumor proliferation, apoptosis, and apoptotic-inhibiting markers are concerned [114]. This evidence concerns the gene EGFR and cancer.